Overview

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Status:
Not yet recruiting

Trial end date:
2023-11-22

Target enrollment:

Participant gender:

Summary

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

Phase:

Phase 1

Details

Lead Sponsor:

Novartis Pharmaceuticals